Leap Therapeutics Inc (LPTX) Stock Price, Quote & News

Company Profile

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial. It has an option and...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 714 0360

Website: www.leaptx.com

Address:

47 Thorndike Street, Suite B1-1, Cambridge, United States

Mounting_Mayhem Jul. 14 at 8:51 PM

$LPTX Come on. There's still -0.54% to go for Doug! Don't throw in the towel just yet.

1 · Reply

Mounting_Mayhem Jul. 11 at 7:56 PM

$LPTX Did Walter's programming not get extended beyond end of June? 😂

1 · Reply

PaulLaurent Jul. 11 at 7:12 PM

🔄📉 Oversold Small Caps Update 🧪🔄 $INTS $ASBP $LPTX $DHAI $AIRE

2 · Reply

RavaK Jul. 11 at 7:00 PM

$LPTX omg the only hope here is that Doug dumps all the extra cash into a “Bitcoin strategic reserve” and fires everyone in the company. Just came to see what’s happening with this old loser investment of mine- Good luck to you all!!

0 · Reply

kamikaze_andy Jul. 11 at 3:54 PM

$LPTX what’s going on with the investigator-sponsored endometrial study ? They did have one ‘complete response’

1 · Reply

OracleoftheBayou Jul. 10 at 6:45 PM

$LPTX give me at least $1 a share buyout please. There has to be some value in our pipeline

0 · Reply

Chuckyboss1 Jul. 9 at 7:43 PM

$LPTX there’s something wrong here it’s up or is my screen messed up

0 · Reply

kamikaze_andy Jul. 9 at 2:40 PM

$LPTX they should post a for sale ad Facebook marketplace .

1 · Reply

Sunnym15 Jul. 9 at 3:23 AM

$LPTX I refuse to believe people are actively buying this crap.

1 · Reply

deano361 Jul. 8 at 2:31 PM

$LPTX We going to get a dead cat bounce at some level?

1 · Reply

Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic Alternatives

May 13, 2025, 7:00 AM EDT - 2 months ago

Leap Therapeutics Reports First Quarter 2025 Financial Results

Apr 25, 2025, 1:00 PM EDT - 2 months ago

Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting

Apr 15, 2025, 7:00 AM EDT - 3 months ago

Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer

Mar 31, 2025, 1:42 PM EDT - 3 months ago

Leap Therapeutics (LPTX) Conference Call to discuss Updated Data from Part B of the DeFianCe Study Transcript

Mar 26, 2025, 1:29 PM EDT - 3 months ago

Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer

Mar 26, 2025, 7:05 AM EDT - 3 months ago

Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 26, 2025, 7:00 AM EDT - 3 months ago

Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study

Jan 28, 2025, 7:00 AM EST - 6 months ago

Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study

Jan 6, 2025, 7:01 AM EST - 6 months ago

Leap Therapeutics: A Buy On Near-Term Data Catalysts In Stomach And Colon Cancer

Jan 6, 2025, 7:00 AM EST - 6 months ago

Leap Therapeutics to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 26, 2024, 7:00 AM EST - 8 months ago

Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference

Nov 13, 2024, 7:00 AM EST - 8 months ago

Leap Therapeutics Reports Third Quarter 2024 Financial Results

Sep 30, 2024, 7:00 AM EDT - 10 months ago

Leap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

Aug 12, 2024, 7:00 AM EDT - 1 year ago

Leap Therapeutics Reports Second Quarter 2024 Financial Results

May 13, 2024, 7:00 AM EDT - 1 year ago

Leap Therapeutics Reports First Quarter 2024 Financial Results

Apr 11, 2024, 8:30 AM EDT - 1 year ago

Leap Therapeutics Announces $40 Million Private Placement

Mar 18, 2024, 7:00 AM EDT - 1 year ago

Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Jan 16, 2024, 5:05 PM EST - 1 year ago

Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium

Jan 3, 2024, 7:00 AM EST - 1 year ago

Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 2, 2024, 7:00 AM EST - 1 year ago

Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients

Dec 11, 2023, 4:05 PM EST - 1 year ago

Leap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers Symposium

Nov 21, 2023, 7:00 AM EST - 1 year ago

Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare Conference

Nov 13, 2023, 7:00 AM EST - 1 year ago

Leap Therapeutics Reports Third Quarter 2023 Financial Results

Sep 5, 2023, 7:00 AM EDT - 2 years ago

Leap Therapeutics to Participate at Upcoming Investor Conferences

Aug 14, 2023, 7:00 AM EDT - 2 years ago

Leap Therapeutics Reports Second Quarter 2023 Financial Results

Jul 12, 2023, 7:00 AM EDT - 2 years ago

Leap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer Patients

Jun 20, 2023, 12:30 PM EDT - 2 years ago

Leap Therapeutics Announces Reverse Stock Split

May 25, 2023, 5:10 PM EDT - 2 years ago

Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting

May 15, 2023, 7:00 AM EDT - 2 years ago

Leap Therapeutics Reports First Quarter 2023 Financial Results

Apr 12, 2023, 7:00 AM EDT - 2 years ago

Leap Therapeutics Announces Completion of Enrollment in Part A of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

Mar 24, 2023, 7:00 AM EDT - 2 years ago

Leap Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Mar 16, 2023, 4:05 PM EDT - 2 years ago

Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01

Jan 17, 2023, 8:00 AM EST - 2 years ago

Leap Therapeutics Acquires Flame Biosciences

Jan 11, 2023, 7:00 AM EST - 2 years ago

Leap Therapeutics to Present at B. Riley Securities' 3rd Annual Oncology Conference

Nov 21, 2022, 7:00 AM EST - 2 years ago

Leap Therapeutics to Participate at the Piper Sandler 34th Annual Healthcare Conference

Nov 14, 2022, 7:00 AM EST - 2 years ago

Leap Therapeutics Reports Third Quarter 2022 Financial Results

Nov 7, 2022, 8:05 AM EST - 2 years ago

Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting

Oct 17, 2022, 7:00 AM EDT - 2 years ago

Leap Therapeutics Announces First Patient Enrolled in DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

Oct 12, 2022, 7:00 AM EDT - 2 years ago

Leap Therapeutics Announces First Patient Enrolled in Part C of Phase 2 DisTinGuish Study of DKN-01 in Combination with Tislelizumab for the Treatment of Gastric or Gastroesophageal Junction Cancer

Sep 7, 2022, 7:00 AM EDT - 3 years ago

Leap Therapeutics to Participate at the Baird 2022 Global Healthcare Conference

Sep 6, 2022, 7:00 AM EDT - 3 years ago

Leap Therapeutics Announces Appointment of Richard L. Schilsky, MD to its Board of Directors

Sep 4, 2022, 6:05 PM EDT - 3 years ago

Leap Therapeutics to Present New Data from DisTinGuish Study of DKN-01 Plus Tislelizumab and WAKING Study of DKN-01 Plus Tecentriq® at the ESMO Congress

Aug 12, 2022, 7:00 AM EDT - 3 years ago

Leap Therapeutics Reports Second Quarter 2022 Financial Results

Aug 12, 2022, 7:00 AM EDT - 3 years ago

Leap Therapeutics' Board of Directors Member Dr. Monica Bertagnolli Appointed as the Director of the National Cancer Institute

Jul 12, 2022, 7:00 AM EDT - 3 years ago

Leap Therapeutics Announces Initiation of New DKN-01 Clinical Trials in Gastric Cancer, Colorectal Cancer and Endometrial Cancer

ONC

Mounting_Mayhem Jul. 14 at 8:51 PM

$LPTX Come on. There's still -0.54% to go for Doug! Don't throw in the towel just yet.

1 · Reply

Mounting_Mayhem Jul. 11 at 7:56 PM

$LPTX Did Walter's programming not get extended beyond end of June? 😂

1 · Reply

PaulLaurent Jul. 11 at 7:12 PM

🔄📉 Oversold Small Caps Update 🧪🔄 $INTS $ASBP $LPTX $DHAI $AIRE

2 · Reply

RavaK Jul. 11 at 7:00 PM

0 · Reply

kamikaze_andy Jul. 11 at 3:54 PM

$LPTX what’s going on with the investigator-sponsored endometrial study ? They did have one ‘complete response’

1 · Reply

OracleoftheBayou Jul. 10 at 6:45 PM

$LPTX give me at least $1 a share buyout please. There has to be some value in our pipeline

0 · Reply

Chuckyboss1 Jul. 9 at 7:43 PM

$LPTX there’s something wrong here it’s up or is my screen messed up

0 · Reply

kamikaze_andy Jul. 9 at 2:40 PM

$LPTX they should post a for sale ad Facebook marketplace .

1 · Reply

Sunnym15 Jul. 9 at 3:23 AM

$LPTX I refuse to believe people are actively buying this crap.

1 · Reply

deano361 Jul. 8 at 2:31 PM

$LPTX We going to get a dead cat bounce at some level?

1 · Reply

Biotech_Beast Jul. 8 at 2:01 PM

$LPTX What a shame to see DKN-01 sitting round. A redo of Defiance in the high DKK1 group is so important. Patients need that drug.

1 · Reply

Universaal Jul. 5 at 7:13 AM

$LPTX what are these guys doing now ?? If they have nothing in their pipeline? Just eating out leftover cash??

1 · Reply

Universaal Jul. 3 at 9:26 PM

$LPTX any future here to average here??

2 · Reply

ErrantLife Jul. 2 at 2:27 PM

$LPTX 3 Form- 4s, Chief rats fleeing the sinking ship?

3 · Reply

deano361 Jul. 2 at 12:30 PM

$LPTX let’s go Doug, don’t be stubborn. Get us a fair price.

0 · Reply

Drugtrade Jul. 1 at 6:03 PM

$LPTX cmon lets hit 50 cents again first then stabilize i can wait

0 · Reply

MurrayK Jul. 1 at 5:47 AM

$LPTX wouldn’t you just know it!! As soon as I sell my 2021 shares, this thing pops. I’m out about 7 cents. Wtf!!!

0 · Reply

Justgivememymoney Jun. 30 at 5:51 PM

$LPTX Going for a run! 🚀

0 · Reply

Chuckyboss1 Jun. 30 at 5:24 PM

$LPTX capster bio just bought out for billions cancer drugs are backin the limelight as they should be they save lives and the world needs to fund more research

0 · Reply

Chuckyboss1 Jun. 30 at 5:23 PM

$LPTX VOR leaps neighbor now up over 500%

1 · Reply

deano361 Jun. 30 at 12:40 PM

$LPTX how long does Doug shop for buyers you think? Two months , six months , or more? No trials and 25% employment base seems like they got a lot of time.

3 · Reply

deano361 Jun. 28 at 5:04 PM

$LPTX this will either be zero 0️⃣ f no buyers or $1 + if Raymond stirs interest

0 · Reply

Market Cap	13.67M
Revenue (ttm)	0.00
Net Income (ttm)	-67.56M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	276,400
Avg Vol	1,504,298
Day's Range	N/A - N/A
Shares Out	41.44M
Stochastic %K	66%
Beta	-0.28
Analysts	Hold
Price Target	$1.25